Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.biOasis Technologies has announced the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company’s Transcend BBB delivery vector.
Subscribe to our email newsletter
biOasis’ Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97).
Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would bind to specific receptors for this protein thus initiating transport across the BBB through a process know as Receptor Mediated Transcytosis.
Work to show that this is indeed correct has resulted in issuance of a patent entitled "P97 Fragments with Transfer Activity".
biOasis CEO Rob Hutchison said: "As our team worked with Transcend in pre-clinical models to prove its utility to delivery therapeutic agents across the BBB, they also conducted over four years of experiments to find active polypeptide fragments from within the 738 amino acid sequence of Transcend that where involved in binding specific receptors that are involved in transport through the BBB.
"As we embarked down that lengthy process we made a number of discoveries. In 2010 we set in place a strategic plan to broaden and securely protect the assets of the Company, this patent was a key part of that journey.
Intellectual Property, patents, are a key cornerstone to our commercial licensing strategy and as these patents issue, our license models increase in value, thereby increasing the overall value of the Transcend Platform."